eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.

Sara M. Tolaney, Shom Goel, Peter A. Kaufman et al.|Journal of Clinical Oncology|2021

Cited by 1